Russell Pachynski

Russell Pachynski

Company: Washington University School of Medicine

Job title: Associate Professor

Seminars:

Altering the Human Prostate Tumor Immune Microenvironment Through Inhibition of Ibrutinib 2:45 pm

This is the first clinical trial of the BTK inhibitor ibrutinib in prostate cancer Ibrutinib may alter favorably alter the prostate tumor microenvironment by reducing pro-tumor B cells and increasing anti-tumor T cells Inhibition of BTK may also limit tumor cell-intrinsic growth Prostate tissue and peripheral correlative studies will be performed to evaluate the further…Read more

day: Day Two

Altering the Human Prostate Tumor Immune Microenvironment Through Inhibition of Ibrutinib 2:45 pm

This is the first clinical trial of the BTK inhibitor ibrutinib in prostate cancer Ibrutinib may alter favorably alter the prostate tumor microenvironment by reducing pro-tumor B cells and increasing anti-tumor T cells Inhibition of BTK may also limit tumor cell-intrinsic growth Prostate tissue and peripheral correlative studies will be performed to evaluate the further…Read more

day: Pre-Conference Focus Day

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.